Real-World Evidence for the Safety and Efficacy of CGRP Monoclonal Antibody Therapy Added to OnabotulinumtoxinA Treatment for Migraine Prevention in Adult Patients With Chronic Migraine
Source : https://www.frontiersin.org/articles/10.3389/fneur.2021.788159/full
Background: OnabotulinumtoxinA and calcitonin gene-related peptide (CGRP) monoclonal antibodies (mAbs) target different migraine pathways, therefore, combination treatment may provide additional effectiveness for the preventive treatment of chronic migraine (CM) than...
Conclusion: In this real-world study, onabotulinumtoxinA was effective at reducing MHD and the addition of a CGRP mAb was safe, well-tolerated and associated with incremental and clinically meaningful reductions in MHD for those who stayed on the combination treatment. No new safety signals were identified. Of those who discontinued, the...
-
Huma Sheikh, CEO, NY Neurology Medicine, PC4yrStudies like these are so needed so insurances companies can start to cover these quickly.
Patient-reported outcomes of migraine treatment with erenumab: results from a national patient survey - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35006445/
Vast majority of patients experience stable or increasing effect of erenumab. * Erenumab efficacy usually becomes evident during the first month of treatment. * Erenumab is perceived significantly better than...
Conclusion: After treatment discontinuation, a rapid migraine worsening was found, despite the high clinical response during treatment and at retreatment, which might be secondary to an untimely interruption of a potentially disease-modifying pharmacologic intervention. Although clinical improvement was documented after retreatment, given the...
-
Huma Sheikh, CEO, NY Neurology Medicine, PC4yrHopefully, these will lead to insurances approving these quicker.
Erenumab Discontinuation After 12-Month Treatment
Source : https://cp.neurology.org/content/11/6/e834
Objective To assess migraine outcome after 12-month treatment with erenumab and compare patients who underwent 3-month erenumab discontinuation following the first treatment cycle with those who continued monthly administrations. Methods...
Conclusion: Erenumab is perceived as an effective and safe treatment. Further studies are needed to investigate a post-cessation deterioration of achieved improvement.
-
Huma Sheikh, CEO, NY Neurology Medicine, PC4yrThis is quite an interesting study.
-
Migraine Connect4yrKey Points • Source: Neurology Clinical Practice • Conclusions/Relevance: “After treatment discontinuation, a rapid migraine worsening was found, despite the high clinical response during treatment and at retreatment, which might be secondary to an Show More
TRUDHESA DHE (DIHYDROERGOTAMINE) NASAL SPRAY, AND THE TOP 7 REASONS TO CONSIDER DHE FOR MIGRAINE TREATMENT. - Virtual Headache Specialist
Intravenous DHE (dihydroergotamine) has always been considered to be one of the most effective medicines in treating refractory migraine and status migrainosus when other medicines such as triptans won't work....
-
Migraine Connect4yrThanks for your contributions [~Dr--Hamid--ayeshahameed09@ ] and [~Huma--Sheikh--huma927@ ] ! What do others think of these new options?
Show More Comments
Gender Differences in 3-Month Outcomes of Erenumab Treatment-Study on Efficacy and Safety of Treatment With Erenumab in Men
Source : https://www.frontiersin.org/articles/10.3389/fneur.2021.774341/full
Objective: We reported gender-specific data on the efficacy and safety of erenumab, a monoclonal antibody antagonizing the calcitonin gene-related peptide (CGRP) receptor.Methods: Our pooled patient-level analysis of real-world data included...
Conclusion: We found that erenumab is equally safe and effective in men compared with women after 12 weeks.